Patients in the UK with relapsed or refractory mantle cell lymphoma have access to the drug ibrutinib through the MED (Medicines Evaluation Board) compassionate use programme.
News and views
We've now released videos of our 2014 patient and carer conference which you can watch online or on DVD.
It’s just been announced that some people with low-grade non-Hodgkin lymphoma or mantle cell lymphoma in England will soon be able to get rituximab (MabThera®) via a 5-minute injection under the skin (a subcutaneous injection).
The deadline for nominations for the 2014 Beacons of Hope Awards has been extended to
5pm on Monday 4 August.
As part of an ambitious new growth and development phase, we’re recruiting for nine new roles across the charity.
Blood cancer charity Leukaemia and Lymphoma Research have launched a new project to research the needs of blood cancer patients. You can inform the work of Leukaemia and Lymphoma research by completing this online survey now.
A form of rituximab (MabThera®) which can be injected into the layer of fat beneath the skin has just become available to some people with non-Hodgkin lymphoma (NHL) in Scotland.